Who is sponsoring NCT03109964?

NCT03109964 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT03109964?

Interventions in NCT03109964: Bipolar coagulation forceps (ETHICON inc.), SURGIFLO hemostatic matrix (ETHICON inc.).

What condition does NCT03109964 study?

NCT03109964 studies Cyst Ovary.

Is NCT03109964 still recruiting?

NCT03109964 is currently completed. Last updated 26 October 2022.

Last reviewed 2022-10-26 · How we verify

NCT03109964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Affect of Hemostasis Technique During Laparoscopic Ovarian Cystectomy on Future Fertility

Completed NA Last updated 26 October 2022

What this trial tests

NA trial testing Bipolar coagulation forceps (ETHICON inc.) in Cyst Ovary in 127 participants. Completed in 1 August 2022.

Timeline

20 November 2018

Primary endpoint
31 March 2021

1 August 2022

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	127
Start date	20 November 2018
Primary completion	31 March 2021
Estimated completion	1 August 2022
Sites	1 location across Israel

Drugs / interventions tested

Bipolar coagulation forceps (ETHICON inc.)
SURGIFLO hemostatic matrix (ETHICON inc.)

Conditions studied

Cyst Ovary — all drugs for Cyst Ovary →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

Adults 18 to 44, female only, with Cyst Ovary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients undergoing elective laparoscopic ovarian cystectomy will be recruited and randomly divided into 2 groups according to intervention technique-half will be allocated to the bipolar coagulation group and half to the SURGIFLO group. Patients will be assessed both pre-operatively and 6 months post-operatively by blood tests including follicle stimulating hormone (FSH), lutenizing hormone (LH), Estrogen (E2), Progesterone and anti-mullerian hormone (AMH) levels, and sonographic evaluation of ovarian volume and antral follicle count.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03109964 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 26 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03109964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing